Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab in severe COVID-19
IRCT20150303021315N17Phase 3Completed
- Sponsor
- AryoGen Biopharma
- Start
- Mar 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of tocilizumab in coronavirus disease 2019 (COVID-19), sponsored by AryoGen Biopharma. Primary endpoint: All-cause mortality rate during the study. Started Mar 2020; status: completed.
02
Drugs
tocilizumab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20150303021315N17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20150303021315N17.